Exciting Updates on Lifiravant for NSCLC and Enhanced Survival Outcomes Presented at WCLC 2026 #United_States #NSCLC #Librofaz #Lifiravant #Raritan,_New_Jersey

New Approval for Librofaz®: Boosting Convenience in Lung Cancer Treatment #Japan #Johnson_&_Johnson #Tokyo #NSCLC #Librofaz®